挽救性机器人辅助肾手术的分类、技术与结局
结果显示sRAPN术中并发症率33%,sRARN术后并发症率7%;3年局部无复发生存在sRAPN和sRARN分别为64%和82%,提示并发症可控但局部复发风险不可忽视。
要点
- 挽救性机器人肾手术并发症总体可控,但sRAPN术中并发症率达33%。
- sRAPN与sRARN的3年局部无复发率分别为64%和82%。
- 既往局部消融后挽救性sRAPN的3年无转移生存率为90%。
核心结论
- 经验丰富的高容量中心行挽救性机器人辅助肾手术并发症可控,但局部复发风险不可忽视。
主要发现
- 既往部分肾切除后32例接受挽救手术,其中sRAPN 2例、sRARN 10例用于同肾异时性复发,无术中或围术期并发症。
- 切除床局部复发者中,6例行sRAPN(术中并发症率33%,无术后并发症),14例行sRARN(无术中并发症,术后并发症率7%)。
- sRAPN和sRARN的3年局部无复发率分别为64%和82%,3年无转移生存率分别为80%和79%。
- 既往局部消融后35例均行sRAPN,无术中并发症,总体术后并发症率20%,无局部复发,3年无转移生存率90%。
关键数值与推荐
- sRAPN术后33个月中位eGFR为57 ml/min/1.73 m2,sRARN为45 ml/min/1.73 m2。
- 既往局部消融后sRAPN术后43个月中位eGFR为38 ml/min/1.73 m2。
临床怎么用
- 对部分肾切除或局部消融后局部复发的肾癌患者,可考虑在有经验的中心行挽救性机器人手术。
- 术前应告知患者局部复发风险非 negligible,需个体化选择sRAPN或sRARN。
局限性
- 样本量相对较小且为非比较性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Salvage treatment for local recurrence after prior partial nephrectomy (PN) or local tumor ablation (LTA) for kidney cancer is, as of yet, poorly investigated. OBJECTIVE: To classify the treatments and standardize the nomenclature of salvage robot-assisted renal surgery, to describe the surgical technique for each scenario, and to investigate complications, renal function, and oncologic outcomes. DESIGN, SETTING, AND PARTICIPANTS: Sixty-seven patients underwent salvage robot-assisted renal surgery from October 2010 to December 2020 at nine tertiary referral centers. SURGICAL PROCEDURE: Salvage robot-assisted renal surgery classified according to treatment type as salvage robot-assisted partial or radical nephrectomy (sRAPN or sRARN) and according to previous primary treatment (PN or LTA). MEASUREMENTS: Postoperative complications, renal function, and oncologic outcomes were assessed. RESULTS AND LIMITATIONS: A total of 32 and 35 patients underwent salvage robotic surgery following PN and LTA, respectively. After prior PN, two patients underwent sRAPN, while ten underwent sRARN for a metachronous recurrence in the same kidney. No intra- or perioperative complication occurred. For local recurrence in the resection bed, six patients underwent sRAPN, while 14 underwent sRARN. For sRAPN, the intraoperative complication rate was 33%; there was no postoperative complication. For sRARN, there was no intraoperative complication and the postoperative complication rate was 7%. At 3 yr, the local recurrence-free rates were 64% and 82% for sRAPN and sRARN, respectively, while the 3-yr metastasis-free rates were 80% and 79%, respectively. At 33 mo, the median estimated glomerular filtration rates (eGFRs) were 57 and 45 ml/min/1.73 m2 for sRAPN and sRARN, respectively. After prior LTA, 35 patients underwent sRAPN and no patient underwent sRARN. There was no intraoperative complication; the overall postoperative complications rate was 20%. No local recurrence occurred. The 3-yr metastasis-free rate was 90%. At 43 mo, the median eGFR was 38 ml/min/1.73 m2. The main limitations are the relatively small population and the noncomparative design of the study. CONCLUSIONS: Salvage robot-assisted surgery has a safe complication profile in the hands of experienced surgeons at high-volume institutions, but the risk of local recurrence in this setting is non-negligible. PATIENT SUMMARY: Patients with local recurrence after partial nephrectomy or local tumor ablation should be aware that further treatment with robot-assisted surgery is not associated with a worrisome complication profile, but also that they are at risk of further recurrence.
引用
- Martini A, Turri F, Barod R, et al. Salvage Robot-assisted Renal Surgery for Local Recurrence After Surgical Resection or Renal Mass Ablation: Classification, Techniques, and Clinical Outcomes. Eur Urol. 2021. PMID: 34088520. doi:10.1016/j.eururo.2021.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。